Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:10
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 42 条
[1]   Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Ageno, Walter ;
Gallus, Alexander S. ;
Wittkowsky, Ann ;
Crowther, Mark ;
Hylek, Elaine M. ;
Palareti, Gualtiero .
CHEST, 2012, 141 (02) :E44S-E88S
[2]   Questionable reversal of anticoagulation in the therapeutic management of cerebral haemorrhage associated with vitamin K antagonists [J].
Alonso de Lecinana, Maria ;
Huertas, Nuria ;
Egido, Jose A. ;
Muriel, Alfonso ;
Garcia, Ana ;
Ruiz-Aress, Gerardo ;
Diez-Tejedor, Exuperio ;
Fuentes, Blanca .
THROMBOSIS AND HAEMOSTASIS, 2013, 110 (06) :1145-1151
[3]   Use of factor IX complex in warfarin-related intracranial hemorrhage [J].
Boulis, NM ;
Bobek, MP ;
Schmaier, A ;
Hoff, JT .
NEUROSURGERY, 1999, 45 (05) :1113-1118
[4]  
Cartmill M, 2000, BRIT J NEUROSURG, V14, P458
[5]   Warfarin-associated intracerebral hemorrhage [J].
Cavallini, Anna ;
Fanucchi, Simona ;
Persico, Alessandra .
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) :S266-S268
[6]   Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis [J].
Chai-Adisaksopha, Chatree ;
Hillis, Christopher ;
Siegal, Deborah M. ;
Movilla, Ron ;
Heddle, Nancy ;
Iorio, Alfonso ;
Crowther, Mark .
THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) :879-890
[7]   Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage [J].
Ciccone, Alfonso ;
Pozzi, Mario ;
Motto, Cristina ;
Tiraboschi, Pietro ;
Sterzi, Roberto .
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) :S256-S257
[8]   Reversal of anticoagulation in trauma: A North American survey on clinical practices among trauma surgeons [J].
Coimbra, R ;
Hoyt, DB ;
Anjaria, DJ ;
Potenza, BM ;
Fortlage, D ;
Hollingsworth-Fridlund, P .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2005, 59 (02) :374-381
[9]   Use of three procoagulants in improving bleeding outcomes in the warfarin patient with intracranial hemorrhage [J].
DeLoughery, Emma P. ;
DeLoughery, Thomas G. .
BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (08) :612-616
[10]   Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis [J].
Dentali, Francesco ;
Marchesi, Chiara ;
Pierfranceschi, Matteo Giorgi ;
Crowther, Mark ;
Garcia, David ;
Hylek, Elaine ;
Witt, Daniel M. ;
Clark, Nathan P. ;
Squizzato, Alessandro ;
Imberti, Davide ;
Ageno, Walter .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) :429-438